CAMH is committed to translating scientific discoveries into practical applications to help understand, diagnose and treat not only substance use disorder and mental illness but also to promote cutting edge technologies that could transform biology or treatment of disease. View PDF files below for more information on CAMH technologies that are available for licensing: ​
​​

• Cell-Free Circulating DNA in Bodily Fluids
• Diagnosis and Treatment of Mood Disorders
  
• Diagnostics of Intellectual Disability TRAPC9 and NSUN2 Genes
  
• DNA Methylation Changes Associated with Major Psychosis 
  
• Genetic Marker for Anxiety Disorder 
  
• Novel Atypical Antipsychotic Small Molecules 
  
• Peptide Therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) ​
  
• Peptide Therapeutics for Depression Treatment
  
• Peptide Therapeutics for Multiple Sclerosis
  
• Peptide Therapeutics for Nicotine and Alcohol Addiction 
  
• Peptide Therapeutics - Novel Antipsycotics ​
  
• Peptide Therapeutics for Stroke
• Problem Gambling Online and Mobile Resources
• Technology for Large-Scale DNA Methylation Profiling

 
 
   

    
   
      

   
      
 ​​​​